GlobeNewswire Inc | Mar 3, 2021 08:00AM EST

March 03, 2021

SAN FRANCISCO, March 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Companys Management will participate in the virtual H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Tuesday, March 9, 2021. An archived webcast will also be accessible in the investor section of89bios website.

About 89bio 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The companys lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact: Ryan Martins Chief Financial Officer investors@89bio.com

Media Contact: Peter Duckler 773-343-3069 pduckler@w2ogroup.com